Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma

Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2025) 146 (Supplement 1): 1756.

https://doi.org/10.1182/blood-2025-1756

Published: 2025

Journal Articles

Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features

Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2025) 146 (Supplement 1): 5311.

https://doi.org/10.1182/blood-2025-5311

Published: 2025

Journal Articles

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Won-Seog Kim, Dok Hyun Yoon, Youngil Koh, Seok Jin Kim, Sang Eun Yoon, Hyungwoo Cho, Jaewon Hyung, Ja Min Byun, Hyesung Jeon, Seungryel Han

Blood (2025) 146 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2025-1043

Published: 2025

Journal Articles

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Won Seog Kim, Seok Jin Kim, Jae-Cheol Cho, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Heung Tae Kim

Blood (2025) 146 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2025-5426

Published: 2025

Journal Articles

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)

Dok Hyun Yoon, Hyungwoo Cho, Jaewon Hyung, Yoon Seok Choi, Youngwoo Jeon, Seok Jin Kim, Youngil Koh, Nari Yun, Woohyung Lee, Chanmi Kim, Myoung Ho Jang

Blood (2025) 146 (Supplement 1): 2399.

https://doi.org/10.1182/blood-2025-2399

Published: 2025

Journal Articles

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma

Dong Hyun Kim, Sanyeowool An, Ka-Won Kang, Sang Eun Yoon, Seok Jin Kim, Hyo Jung Kim, Youngil Koh, Deok-Hwan Yang

Blood (2025) 146 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2025-3692

Published: 2025

Journal Articles

Prognostic significance of post-treatment EBV clearance and relapse patterns in localized extranodal NK/T-cell lymphoma treated with low-dose radiotherapy: A single-center analysis of 155 patients

Yoon Sang Eun, Dongryul Oh, Junhun Cho, Seok Jin Kim, Won-Seog Kim

Blood (2025) 146 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2025-1873

Published: 2025

Journal Articles

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Blood (2025) 146 (2): 155–166.

https://doi.org/10.1182/blood.2024027109

Published: 2025

Includes: Supplemental data

Journal Articles

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Seok Jin Kim, SangEun Yoon, Ji Hyun Lee, Jeong-Ok Lee, Seong Hyun Jeong, Sung-Nam Lim, Ho-Jin Shin, Duck Hwan Yang, Won Seog Kim

Blood (2024) 144 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2024-205026

Published: 2024

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Blood (2024) 144 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2024-201533

Published: 2024

Journal Articles

Long-Term Outcomes of Bronchus-Associated Lymphoid Tissue Lymphoma Based on Lung Involvement Status: A Single-Center Real-World Data Analysis in Korea

Changgon Kim, Seok Jin Kim, Won Seog Kim, SangEun Yoon

Blood (2024) 144 (Supplement 1): 6309.

https://doi.org/10.1182/blood-2024-206547

Published: 2024

Journal Articles

The Reason Why We Should Differentiate Monomorphic Epitheliotropic T Cell Lymphoma and Intestinal T Cell Lymphoma, NOS - a Retrospective Study about the Experience of a Single Tertiary Hospital in Korea

Jiyeon Hyeon, Changgon Kim, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Junhun Cho, Won Seog Kim

Blood (2024) 144 (Supplement 1): 6419.

https://doi.org/10.1182/blood-2024-210911

Published: 2024

Journal Articles

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Sang Eun Yoon, Sung-Hoon Jung, Gyeong Won Lee, Chang-Ki Min, Ja Min Byun, Jae-Yong Kwak, Myung-Won Lee, Ho Sup Lee, Seok Jin Kim, Kihyun Kim

Blood (2024) 144 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2024-198947

Published: 2024

Journal Articles

Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Changgon Kim, SangEun Yoon, Hyun-Young Kim, Duck Cho, Hong Hoe Koo, Junhun Cho, Won Seog Kim, Seok Jin Kim

Blood (2024) 144 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2024-204987

Published: 2024

Journal Articles

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Jordan S Goldstein, Mark Roschewski, Won-Seog Kim, Sang Eun Yoon, Seok Jin Kim, Jason R. Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob Chabon, Davide Rossi, Wyndham H. Wilson, David Kurtz, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 651.

https://doi.org/10.1182/blood-2024-211068

Published: 2024

Journal Articles

Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Seok Jin Kim, SangEun Yoon, Woorim Kang, Mauricio Chalita, Hong Hoe Koo, Dong-Wook Hyun, Hyun Kim, Junhun Cho, Won Seog Kim

Blood (2024) 144 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2024-205074

Published: 2024

Journal Articles

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2024) 144 (6): 629–638.

https://doi.org/10.1182/blood.2023023419

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Data of Outcome of Patients with Newly Diagnosed Bronchial-Associated Lymphoid Tissue Lymphoma: A Multi-Center Retrospective Analysis with Long-Term Survivors

Kunye Kwak, Yong Park, Byung Soo Kim, Sang Eun Yoon, Won Seog Kim, Kwai Han Yoo, Ka-Won Kang, Seok Jin Kim

Blood (2023) 142 (Supplement 1): 6143.

https://doi.org/10.1182/blood-2023-188254

Published: 2023

Journal Articles

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Jun Ho Yi, Seok Jin Kim, Sang A Kim, Jongheon Jung, Dok Hyun Yoon

Blood (2023) 142 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2023-186554

Published: 2023

Journal Articles

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Seok Jin Kim, Myung-Won Lee, Sung-Nam Lim, Ka-Won Kang, Sang Eun Yoon, Yoo Jin Lee, Hye Jin Kang, Ho Sup Lee, Hyo Jung Kim, Hong Hoe Koo, Ho-Jin Shin, Hyeon-Seok Eom, Jong-Ho Won, Won Seog Kim

Blood (2023) 142 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2023-181809

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma

Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma

Prognostic significance of post-treatment EBV clearance and relapse patterns in localized extranodal NK/T-cell lymphoma treated with low-dose radiotherapy: A single-center analysis of 155 patients

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Long-Term Outcomes of Bronchus-Associated Lymphoid Tissue Lymphoma Based on Lung Involvement Status: A Single-Center Real-World Data Analysis in Korea

The Reason Why We Should Differentiate Monomorphic Epitheliotropic T Cell Lymphoma and Intestinal T Cell Lymphoma, NOS - a Retrospective Study about the Experience of a Single Tertiary Hospital in Korea

A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Real-World Data of Outcome of Patients with Newly Diagnosed Bronchial-Associated Lymphoid Tissue Lymphoma: A Multi-Center Retrospective Analysis with Long-Term Survivors

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only